HC Wainwright Predicts Alumis' Q3 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at HC Wainwright issued their Q3 2024 EPS estimates for Alumis in a research report issued to clients and investors on Thursday, October 17th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($2.27) for the quarter. HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Alumis' current full-year earnings is ($6.86) per share. HC Wainwright also issued estimates for Alumis' Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($11.42) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.24) EPS and FY2025 earnings at ($4.90) EPS.

Several other research firms have also recently weighed in on ALMS. Guggenheim started coverage on Alumis in a report on Tuesday, July 23rd. They set a "buy" rating and a $32.00 price objective on the stock. Leerink Partnrs raised shares of Alumis to a "strong-buy" rating in a research report on Tuesday, July 23rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Monday, August 19th. Morgan Stanley began coverage on Alumis in a report on Tuesday, July 23rd. They set an "overweight" rating and a $36.00 price objective for the company. Finally, Leerink Partners started coverage on Alumis in a research report on Tuesday, July 23rd. They issued an "outperform" rating and a $29.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Alumis has a consensus rating of "Buy" and a consensus target price of $28.00.

Alumis Stock Up 4.6 %

Shares of NASDAQ ALMS traded up $0.55 during midday trading on Monday, reaching $12.58. 122,169 shares of the stock were exchanged, compared to its average volume of 169,716. Alumis has a 12 month low of $9.54 and a 12 month high of $13.53. The business's 50-day moving average is $11.64.

Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53).

Institutional Trading of Alumis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Maven Securities LTD acquired a new stake in Alumis in the second quarter valued at $332,000. Millennium Management LLC bought a new position in Alumis during the second quarter worth about $3,376,000. Towerview LLC acquired a new position in Alumis during the second quarter worth approximately $4,123,000. Ally Bridge Group NY LLC bought a new stake in Alumis in the second quarter valued at approximately $8,229,000. Finally, Yu Fan acquired a new stake in shares of Alumis in the second quarter valued at approximately $10,502,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.